ArticleFrontiers in medicine2026
Trends and projections of dermatitis burden (1990-2040): a 2021 global burden of disease analysis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Occupational Contact Dermatitis in the Post-COVID Era: From Barrier Dysfunction and Microbiome Dysbiosis to Prevention and Precision Management.Journal of clinical medicine · 2026Review
- Global Burden of Ovarian Cancer and Causal Risk Factors from 1990 to 2021: An Integrated GBD and Mendelian Randomization Analysis.International journal of women's health · 2026Article
- Population-Level Burden of Dermatitis and the Effects of Moxibustion and Capsaicin on Pruritus and JAK/STAT Signaling in Atopic Dermatitis: A Multilevel Study.Mediators of inflammation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dermatitis is a major global public health challenge. This study evaluates its burden from 1990 to 2021 and projects future burden over the next 20 years. Methods: Data from the Global Burden of Disease Study 2021 (GBD 2021) included prevalence, incidence, disability-adjusted life years (DALYs), and age-standardized rates (ASRs), stratified by year, region, age, and Sociodemographic Index (SDI). Analyses used estimated annual percentage change (EAPC), inequality indices, decomposition, and Bayesian age-period-cohort (BAPC) modeling for forecasting. Results: In 2021, global dermatitis cases reached 241 million (95% UI: 223.3-262.5 million), a 38.8% increase since 1990, but the age-standardized prevalence rate (ASPR) declined to 3,075.1 per 100,000 (EAPC = -0.14). Incident cases were 405 million (95% UI: 356-467 million), with the age-standardized incidence rates (ASIR) slightly increased to 4,945 per 100,000 (EAPC = 0.04). DALYs totaled 8.18 million (95% UI: 4.85-13.0 million), with the age-standardized DALY rate (ASDR) declining to 106.2 per 100,000 (EAPC = -0.18). ASPR and ASDR were highest in high-SDI regions and lowest in low-SDI regions; ASIR negatively correlated with SDI. Incidence peaked at ages 5-9 years. The burden was higher in males. A sharp DALYs rise occurred in those ≥65 years, especially in low/low-middle SDI regions. Projections indicate ASIR will slightly increase to 4,966 per 100,000 by 2040, while ASDR declines to 103 per 100,000. Conclusion: Despite rising absolute cases globally (driven by population growth), declining ASRs suggest diagnostic/therapeutic improvements. Marked disparities persist across SDI levels, age groups, and sexes. Strengthened prevention and resource allocation in low- and middle-income countries are needed to reduce health disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.